The United Kingdom and the United States have signed a major bilateral deal that will maintain no duties on British drug shipments entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost funding on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these key exports will be held at nothing for a timeframe of three years.
This agreement follows previous threats to significantly raise duties on branded drug products, with potential rates discussed up to one hundred percent.
"This agreement between the Britain bolsters the worldwide climate for new treatments and establishes long-overdue fairness to American-British drug exports," an announcement noted.
Trade Impact
Medicines represent one of the UK's most significant export categories to the US, which is by far the primary market for large British pharmaceutical firms.
Export figures show that in the 12 months prior to the third quarter, the UK exported drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This deal safeguards employment, increases funding and paves the way for the UK to emerge as a global hub for medical research," a government official stated.
Detailed UK Commitments
The deal entails several key pledges from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds were more than 20%.
Industry Background
This agreement takes place against a ongoing tension between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were intensified by claims that US patients were charged significantly more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the past decade.
